IOF Blog
Response to JAMA Research Letter Regarding Clinicians Offering Stem Cell Treatments
The June edition of the Journal of the American Medical Association (JAMA) featured a research letter investigating the characteristics and scope of training of clinicians offering stem cell treatments in the U.S.. The findings of the investigation were troubling, yet...
Response to JAMA Research Letter Regarding Clinicians Offering Stem Cell Treatments
The June edition of the Journal of the American Medical Association (JAMA) featured a research letter investigating the characteristics and scope of training of clinicians offering stem cell treatments in the U.S.. The findings of the investigation were troubling, yet...
read more
Rotator Cuff Tear Case Study
Introducing IOF’s Case Study Feature The Interventional Orthopedics Foundation is committed to serving as a resource for physicians pioneering the medical subspecialty of Interventional Orthopedics. In order to best help our members expand their knowledge about...
IOF Launches Ethics Committee; How to Report Unlawful Sale of Medical Products
IOF LAUNCHES ETHICS COMMITTEEFollowing the ban on stem cell therapies in Canada and an increased number of clinicians offering stem cell therapies using non-FDA compliant products, the Interventional Orthopedics Foundation recognized the need to set clear ethical...
FDA Response Regarding Chara Biologics Products
We take our role serving as stewards for our members and the Interventional Orthopedics medical sub-specialty seriously. Recently, our industry has faced several threats including the ban on stem cell therapies in Canada. We have also seen the publication of several...
IOF Expands Course Offerings to Florida and Washington
After hearing requests from Interventional Orthopedics Foundation (IOF) members all across the country, we are excited to announce IOF’s programming is expanding to bring courses to Tampa, Florida and Seattle, Washington. As the regenerative medicine field continues...
Statement from IOF President on the New York Times Article “An Unproven Cure”
As President of the Interventional Orthopedic Foundation, it was with great interest that I read the article by Denise Grady and Reed Abelson: “An Unproven Cure”. This article notes that “stem cell treatments have risen, despite little evidence they work” and goes on...
IOF 2019 Conference Videos Available for Purchase
IOF 2019 Conference Videos Available for Purchase The Interventional Orthopedics Foundation’s 2019 annual conference, #IOF2019: Controversies in Orthobiologics, brought together national and global experts to discuss the latest original research and controversial...
IOF President Receives $590,000 Award to Treat Meniscal Injuries in Military Personnel
Interventional Orthopedics Foundation President Dr. Gerard Malanga, MD has received a research grant to treat active-duty military personnel. Along with Dr. Trevor Dyson-Hudson, MD and Dr. Nathan Hogaboom, PhD, Dr. Malanga received a $590,000 award from the Geneva...
Dr. Ariana DeMers Joins the IOF Board
We are excited to announce the addition of Ariana DeMers, D.O. to the Interventional Orthopedics Foundation Board. “We are thrilled to add Dr. DeMers to our board,” said IOF Chairman Gerard Malanga, M.D. “Her extensive interventional orthopedics experience coupled...
FDA Warning
The U.S. Food & Drug Administration (FDA) has issued a warning letter to Cord for Life, an Altamonte Springs, Florida company that has sold umbilical-cord-blood products to stem cell companies. The FDA also issued 20 letters to companies instructing them to stop...
Birth Tissue Products Consensus and IOF Webinar Recording
The aggressive marketing of birth tissues has been one of the most controversial issues in orthobiologics in recent years. On February 18, 2019, a consensus statement provided by physicians, academics and regulatory experts was published concerning the aggressive...